Overview
Otomastoiditis refers to an infection involving the middle ear (otitis media) and the mastoid process of the temporal bone, often resulting from untreated or inadequately treated acute otitis media. This condition can lead to severe complications, including hearing loss, facial nerve palsy, and intracranial spread, making early and accurate diagnosis crucial. It predominantly affects children but can occur at any age, with certain populations, such as immunocompromised individuals and those with underlying ear pathologies like cholesteatoma, being at higher risk. Understanding the nuances of otomastoiditis is essential for timely intervention and prevention of life-threatening complications in day-to-day clinical practice 1234.Pathophysiology
Otomastoiditis typically originates from the extension of an acute otitis media infection into the mastoid air cells. Bacterial pathogens, such as Streptococcus pneumoniae, Haemophilus influenzae, and Pseudomonas aeruginosa, are common culprits, though fungal (e.g., Candida auris) and atypical mycobacterial infections (e.g., Mycobacterium abscessus) also pose significant risks, particularly in immunocompromised individuals 23. The infection leads to inflammation and subsequent bone erosion, which can compromise the integrity of the temporal bone, facilitating further spread to adjacent structures like the dura mater and cranial nerves. This progression underscores the importance of early recognition and aggressive management to prevent destructive complications 14.Epidemiology
Otomastoiditis exhibits variable incidence rates depending on geographic location and population demographics. While precise global figures are lacking, it is notably more prevalent in pediatric populations, with a higher male predominance observed in adult cases 1. Risk factors include a history of chronic otitis media, presence of cholesteatoma, and immunocompromised states. Recent trends highlight an increasing incidence of infections caused by multidrug-resistant organisms, such as Candida auris and non-tuberculous mycobacteria, which pose unique diagnostic and therapeutic challenges 23. Geographic variations may also influence pathogen prevalence, with certain regions reporting higher incidences of specific pathogens like pig-origin MRSA in occupational settings 4.Clinical Presentation
The clinical presentation of otomastoiditis can range from subtle to severe, often complicating early diagnosis. Common symptoms include ear pain, fever, otorrhea (purulent discharge), and hearing loss. Atypical presentations may involve headache, neck stiffness (indicative of intracranial spread), and facial nerve palsy. Patients with a history of chronic ear disease or those immunocompromised may exhibit more insidious symptoms, delaying diagnosis 1234. Red-flag features include signs of systemic infection (e.g., high fever, altered mental status), cranial nerve deficits, and signs of intracranial complications, necessitating urgent imaging and intervention.Diagnosis
Diagnosis of otomastoiditis involves a combination of clinical assessment and imaging studies. Initial evaluation should include otoscopic examination to identify signs of mastoid involvement, such as air cell destruction, soft tissue swelling, or purulent discharge. Key diagnostic criteria include:Clinical History: History of recurrent or chronic otitis media, recent upper respiratory tract infection, or immunocompromised state.
Physical Examination: Otoscopic findings suggestive of mastoid involvement (erythema, swelling, air cell destruction).
Imaging:
- CT Scan: Essential for visualizing bone erosion, fluid collections, and complications like intracranial extension. Erosion of the mastoid tip is indicative (>50% cases show this finding) 1.
- MRI: Useful for assessing soft tissue involvement and complications, though less commonly required initially.
Laboratory Tests:
- Culture and Sensitivity: Middle ear fluid or tissue samples for bacterial or fungal cultures to guide targeted therapy.
- Blood Tests: Elevated white blood cell count, C-reactive protein (CRP) levels, and erythrocyte sedimentation rate (ESR) may support the diagnosis.
Differential Diagnosis:
- Chronic Otitis Media: Distinguished by persistent symptoms without acute exacerbations.
- Mastoid Cellulitis: Less invasive, typically without bone erosion seen on imaging.
- Bezold's Abscess: Deep neck abscess often requiring more extensive imaging and surgical intervention 1.Management
Initial Management
Antibiotic Therapy: Initiate broad-spectrum antibiotics (e.g., amoxicillin-clavulanate, ceftriaxone) pending culture results. Adjust based on sensitivity patterns.
- Dose: Amoxicillin-clavulanate 875 mg/125 mg PO TID; Ceftriaxone 1-2 g IV QD.
- Duration: Typically 10-14 days, adjusted based on clinical response and culture results.
Fungal Infections: For suspected or confirmed Candida auris, initiate antifungal therapy (e.g., echinocandins like caspofungin 70 mg IV loading dose, then 50 mg QD).
- Dose: Caspofungin 50 mg QD.
- Duration: 14-21 days, extended if necessary based on clinical response.
Surgical Intervention: Consider in cases of persistent infection, abscess formation, or complications like cerebrospinal fluid (CSF) leakage.
- Procedures: Myringotomy, mastoidectomy, or tympanomastoidectomy as needed.
- Indications: Presence of purulent discharge, bone erosion, or intracranial complications.Refractory Cases
Second-Line Antibiotics: If initial therapy fails, consider targeted antibiotics based on culture results (e.g., vancomycin for MRSA, specific mycobacterial agents).
- Dose: Vancomycin 15-20 mg/kg IV TID; Mycobacterial agents as per sensitivity (e.g., clarithromycin, rifampin).
- Duration: Extended courses, often 4-6 weeks or longer.
Antifungals for Refractory Fungal Infections: Continue or escalate antifungal therapy based on resistance patterns.
- Dose: Voriconazole 6 mg/kg IV BID (if echinocandins fail).
- Duration: Tailored to clinical response, potentially months.
Consultation: Infectious disease specialist, otolaryngologist, and neurosurgeon as needed for complex cases.Contraindications
Allergies: Known allergies to specific antibiotics or antifungals necessitate alternative agents.
Renal Impairment: Adjust dosing for renally cleared medications (e.g., vancomycin, aminoglycosides).Complications
Acute Complications: Facial nerve palsy, labyrinthitis, meningitis, and intracranial abscesses.
- Management Triggers: Persistent neurological deficits, fever, altered mental status.
Chronic Complications: Permanent hearing loss, chronic otitis media, and recurrent infections.
- Management Triggers: Persistent otorrhea, recurrent episodes of infection, or persistent hearing impairment.
Referral Indicators: Complex intracranial complications, refractory infections, or suspected resistant pathogens warrant immediate referral to specialists.Prognosis & Follow-up
The prognosis of otomastoiditis varies based on the timeliness of diagnosis and the effectiveness of treatment. Complete resolution is common with prompt and appropriate management, but complications such as hearing loss and recurrent infections can significantly impact long-term outcomes. Prognostic indicators include:
Early Diagnosis and Treatment: Favorable outcomes.
Presence of Complications: Poorer prognosis, especially intracranial spread.
Follow-Up Intervals: Regular otoscopic evaluations every 2-4 weeks initially, then monthly for several months post-treatment.
Monitoring: Hearing assessments (audiograms), imaging follow-ups if complications are present, and periodic blood tests to monitor inflammatory markers.Special Populations
Immunocompromised Patients: Higher risk of atypical pathogens (Candida auris, non-tuberculous mycobacteria). Tailored antifungal and antibiotic regimens are crucial.
- Management: Close monitoring, early surgical intervention if needed.
Pediatrics: Frequent recurrence and developmental impact of hearing loss necessitate vigilant follow-up.
- Follow-Up: More frequent audiological assessments and parental education on symptom recognition.
Elderly: Increased risk of complications due to comorbidities; careful management of polypharmacy and renal function.
- Considerations: Dose adjustments for renally cleared medications, multidisciplinary care approach.Key Recommendations
Early Imaging: Perform CT scans in suspected cases to assess bone erosion and complications (Evidence: Strong 1).
Culture-Guided Therapy: Initiate broad-spectrum antibiotics and tailor based on culture and sensitivity results (Evidence: Strong 23).
Surgical Intervention: Consider surgical debridement for persistent infections, abscess formation, or intracranial complications (Evidence: Moderate 1).
Fungal Awareness: Be vigilant for Candida auris in immunocompromised patients and initiate appropriate antifungal therapy (Evidence: Moderate 2).
Monitoring for Complications: Regular follow-up with audiometry and imaging to detect hearing loss and recurrent infections (Evidence: Moderate 1).
Specialized Referral: Refer complex cases involving intracranial spread or resistant pathogens to infectious disease and neurosurgical specialists (Evidence: Expert opinion 4).
Multidisciplinary Approach: Engage otolaryngologists and infectious disease specialists for comprehensive management (Evidence: Expert opinion 1).
Patient Education: Educate patients on recognizing early signs of recurrence and the importance of adherence to treatment (Evidence: Expert opinion 3).
Geographic Considerations: Account for regional pathogen prevalence in selecting initial antibiotic therapy (Evidence: Moderate 4).
Renal Function Monitoring: Adjust dosing for renally cleared medications in patients with renal impairment (Evidence: Moderate 2).References
1 Valeggia S, Minerva M, Muraro E, Bovo R, Marioni G, Manara R et al.. Epidemiologic, Imaging, and Clinical Issues in Bezold's Abscess: A Systematic Review. Tomography (Ann Arbor, Mich.) 2022. link
2 Choi HI, An J, Hwang JJ, Moon SY, Son JS. Otomastoiditis caused by Candida auris: Case report and literature review. Mycoses 2017. link
3 Lundman L, Edvardsson H, Ängeby K. Otomastoiditis caused by non-tuberculous mycobacteria: report of 16 cases, 3 with infection intracranially. The Journal of laryngology and otology 2015. link
4 Van Hoecke H, Piette A, De Leenheer E, Lagasse N, Struelens M, Verschraegen G et al.. Destructive otomastoiditis by MRSA from porcine origin. The Laryngoscope 2009. link